Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia von Thompson, Philip A., Tam, Constantine S., O'Brien, Susan M., Wierda, William G., Stingo, Francesco, Plunkett, William, Smith, Susan C., Kantarjian, Hagop M., Freireich, Emil J., Keating, Michael J.

Volltext

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia von Jabbour, Elias, O'Brien, Susan, Konopleva, Marina, Kantarjian, Hagop

Volltext

Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy von Burger, Jan A., O’Brien, Susan

Volltext

Initial treatment of CLL: integrating biology and functional status von Jain, Nitin, O'Brien, Susan

Volltext

Monoclonal antibodies in acute lymphoblastic leukemia von Jabbour, Elias, O'Brien, Susan, Ravandi, Farhad, Kantarjian, Hagop

Volltext

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia von Kantarjian, Hagop M, DeAngelo, Daniel J, Stelljes, Matthias, Martinelli, Giovanni, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, O’Brien, Susan, Wang, Kongming, Wang, Tao, Paccagnella, M. Luisa, Sleight, Barbara, Vandendries, Erik, Advani, Anjali S

Volltext

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial von Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech

Volltext

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States von Chen, Qiushi, Jain, Nitin, Ayer, Turgay, Wierda, William G, Flowers, Christopher R, O'Brien, Susan M, Keating, Michael J, Kantarjian, Hagop M, Chhatwal, Jagpreet

Volltext

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials von Allan, John N., Shanafelt, Tait, Wiestner, Adrian, Moreno, Carol, O’Brien, Susan M., Li, Jianling, Krigsfeld, Gabriel, Dean, James P., Ahn, Inhye E.

Volltext

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia von Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M, Stilgenbauer, Stephan

Volltext

Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia von Short, Nicholas J., Jabbour, Elias, Sasaki, Koji, Patel, Keyur, O'Brien, Susan M., Cortes, Jorge E., Garris, Rebecca, Issa, Ghayas C., Garcia-Manero, Guillermo, Luthra, Rajyalakshmi, Thomas, Deborah, Kantarjian, Hagop, Ravandi, Farhad

Volltext

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience von Salles, Gilles, Barrett, Martin, Foà, Robin, Maurer, Joerg, O’Brien, Susan, Valente, Nancy, Wenger, Michael, Maloney, David G.

Volltext

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL von Strati, Paolo, Keating, Michael J., O’Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G.

Volltext

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib von Jain, Preetesh, Keating, Michael, Wierda, William, Estrov, Zeev, Ferrajoli, Alessandra, Jain, Nitin, George, Binsah, James, Danelle, Kantarjian, Hagop, Burger, Jan, O’Brien, Susan

Volltext

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies von Furman, Richard R., Byrd, John C., Owen, Roger G., O’Brien, Susan M., Brown, Jennifer R., Hillmen, Peter, Stephens, Deborah M., Chernyukhin, Nataliya, Lezhava, Tamara, Hamdy, Ahmed M., Izumi, Raquel, Patel, Priti, Baek, Marshall, Christian, Beth, Dyer, Martin J. S., Streetly, Matthew J., Sun, Clare, Rule, Simon, Wang, Michael, Ghia, Paolo, Jurczak, Wojciech, Pagel, John M., Sharman, Jeff P.

Volltext

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy von Thompson, Philip A., Srivastava, Jaya, Peterson, Christine, Strati, Paolo, Jorgensen, Jeffrey L., Hether, Tyler, Keating, Michael J., O'Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Wierda, William G.

Volltext

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma von Hillmen, Peter, Brown, Jennifer R, Eichhorst, Barbara F, Lamanna, Nicole, O'Brien, Susan M, Qiu, Lugui, Salmi, Tommi, Hilger, James, Wu, Kenneth, Cohen, Aileen, Huang, Jane, Tam, Constantine S

Volltext

Acalabrutinib and its use in treatment of chronic lymphocytic leukemia von Khan, Yasir, O'Brien, Susan

Volltext

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimen... von Thompson, Philip A., O'Brien, Susan M., Wierda, William G., Ferrajoli, Alessandra, Stingo, Francesco, Smith, Susan C., Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kantarjian, Hagop M., Keating, Michael J.

Volltext

Emerging data for venetoclax in chronic lymphocytic leukemia von O'Brien, Susan M

Volltext